A University of Pennsylvania team has traced one specific brain wire that the hormone amylin uses to turn down eating, and it runs straight into the brain's reward center. The finding, published October 6 in Diabetes, Obesity and Metabolism ↗, was done in mice and rats. It matters because amylin is the basis for the second wave of obesity drugs now moving through late-stage trials.
Amylin is a hormone the pancreas releases alongside insulin after a meal, and its job is to tell the brain you have eaten enough. Drugmakers are copying it hard. Novo Nordisk's cagrilintide ↗ and Zealand Pharma's petrelintide ↗ are both long-acting amylin mimics in obesity testing, and cagrilintide is one half of CagriSema, the combination with the GLP-1 drug semaglutide ↗. What has stayed fuzzy is where in the brain amylin actually does the work.
The receptor amylin binds, called the calcitonin receptor, sits on scattered clusters of cells across several brain regions. The Penn group, from Matthew Hayes's lab, zeroed in on one of them: the laterodorsal tegmental nucleus, or LDTg, a small brainstem hub wired into reward and motivation. Using dye-based circuit tracing, they showed that the calcitonin-receptor cells there send projections to the ventral tegmental area, the VTA, the dopamine center that assigns value to food and other rewards. The connection held in both mice and rats, and the cells came in two flavors, some that excite their targets and some that quiet them.
Then they tested whether that wire actually carries the appetite signal. Switching the LDTg receptor cells on with chemogenetics, an engineered switch that lets researchers fire specific neurons using a designer molecule, quieted the downstream VTA, measured as a drop in c-Fos, a protein that flags recently active neurons. Snipping the receptor out of only the LDTg-to-VTA link, through a targeted knockdown of Calcr, the receptor's gene, blunted the appetite-suppressing effect of injected salmon calcitonin, an amylin-mimicking research compound, at 6 and 12 hours after the dose. And switching on only the LDTg-to-VTA projection was enough, by itself, to make mice eat less and lose weight.
That last result is the one worth stealing. It places part of amylin's appetite brake not in the classic hunger circuits of the hypothalamus but in the reward system, the same machinery that makes food feel worth eating in the first place. It also fits a separate result from the same lab this summer, that the LDTg reads both amylin and GLP-1 signals and that hitting both there curbs feeding more than either alone, reported in Physiology and Behavior ↗. CagriSema pairs exactly those two signals, which makes a shared brainstem waypoint more than a curiosity.
For the amylin drugs, the practical question has always been how to get the appetite effect without the nausea that has followed the class around. In July we covered a different amylin brain site, the locus coeruleus ↗, where switching on the same receptor cut eating without triggering nausea or raising heart rate. The LDTg-to-VTA wire is a second pin on the map of the calcitonin and amylin receptor ↗, another place the hormone works, and this one is tied specifically to reward rather than to the gut-sickness pathways that drive side effects.
The caveats are the usual ones for this stage. The work is in rodents, the neurons were switched with engineered tools rather than a drug a person could swallow, salmon calcitonin is a lab stand-in for the real hormone, and c-Fos is a proxy for brain activity, not for eating itself. None of that says a pill will land on this exact wire. What it does is hand drug designers a concrete circuit to aim at, and a reason to think an amylin drug could dull the reward of eating without routing through the pathways that leave patients queasy.